Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Fangjian Shang
Observed names:
Fangjian SHANG,
Shang, Fangjian
Institutions:
Hebei Medical University,
First Hospital of Shijiazhuang,
First Affiliated Hospital of Hebei Medical University
Observed institutions:
Hebei Medical University,
Fourth Affiliated Hospital of China Medical University,
First Hospital of Shijiazhuang,
First Affiliated Hospital of Hebei Medical University
ORCID:
0009-0005-2509-1740
Observed ORCID:
0009-0005-2509-1740
OpenAlex ID:
A5102988830
First-Line Treatments for Extensive-Stage Small-Cell Lung Cancer With Immune Checkpoint Inhibitors Plus Chemotherapy: A Network Meta-Analysis and Cost-Effectiveness Analysis
2022
·
Shuo Kang
, Xinchen Wang
, et al.
·
Frontiers in Oncology
·
55
Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status
2021
·
Guoqiang Liu
, Shuo Kang
, et al.
·
Frontiers in Oncology
·
52
PDF
Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China
2023
·
Fangjian Shang
, Boyuan Zhang
, et al.
·
Expert Review of Pharmacoeconomics & Outcomes Research
·
6
Competing-risks model for predicting the prognostic value of lymph nodes in medullary thyroid carcinoma
2023
·
Fangjian Shang
, Xiaodan Liu
, et al.
·
PLoS ONE
·
4
PDF
Polyamine metabolism related gene index prediction of prognosis and immunotherapy response in breast cancer
2025
·
Ruoya Wang
, Shouliang Cai
, et al.
·
Frontiers in Oncology
·
3
A Case of Autologous Reconstruction with TRAM Flap Combined with Contralateral Reduction in Lactational Patient with Breast Cancer and Macromastia
2026
·
Weifang ZHANG
, Yueyao SUN
, et al.
·
DOAJ (DOAJ: Directory of Open Access Journals)
Nomogram for predicting distant metastasis and prognosis in HR+/HER2- breast cancer patients without lymph node metastasis
2023
·
weifang zhang
, Bo Liu
, et al.
·
Research Square
PDF
Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China
2023
·
Shang, Fangjian
, Zhang, Boyuan
, et al.
·
Figshare
Show more works
View as search
Works count:
17
Citation count:
120
H-index:
4
I10-index:
2
Year
Topic
Type